1092523-22-2

Usage

Uses

Used in Pharmaceutical Industry:
6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride is used as an intermediate in the synthesis of SAR131675 (S139510), a potent and selective VEGFR-3 inhibitor. This application is significant because it targets the vascular endothelial growth factor receptor-3 (VEGFR-3), which is involved in the regulation of lymphatic and blood vessel formation. Inhibition of VEGFR-3 can potentially lead to the development of novel treatments for various conditions, including cancer and other diseases characterized by abnormal blood or lymphatic vessel growth.

Upstream product

• 675-14-9 trifluoro-[1,3,5]triazine 
• 1092523-21-1 6-chloro-2-(ethylamino)pyridine-3-carboxylic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 1092523-24-4 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-82-0 2-amino-1-ethyl-7-{4-[2-({[(2S)-1-ethyl-4,4-difluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-66-0 2-amino-1-ethyl-7-{4-[2-({[(2S,4R)-1-ethyl-4-fluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-88-6 2-amino-1-ethyl-N-methyl-7-{4-[2-({[4-(1-methylethyl)morpholin-3-yl]-methyl}amino)-2-oxoethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-56-8 Ethyl {4-[7-amino-8-ethyl-6-(methylcarbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetate 
• 1204651-57-9 {4-[7-Amino-8-ethyl-6-(methyl carbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetic acid 
• 1204651-65-9 C₂₀H₁₉FN₄O₃ 
• 1314069-32-3 2-amino-7-(4-{[(2,3-dichlorophenyl)sulfonyl]amino}-3-fluorophenyl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1412454-13-7 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-[1,8]naphthyridin-4-one 
• 1412453-78-1 2-Amino-1-ethyl-7-[3-(2-fluorophenyl)-3-hydroxybut-1-yn-1-yl]-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one 
• 1412453-77-0 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one 
• 1204536-56-0 2-Amino-1-ethyl-4-oxo-7-[4-(3-pyridin-3-ylmethylureido)phenyl]-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid methylamide 
• 1308917-78-3 C₂₉H₃₇N₅O₄Si 
• 1308917-80-7 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-[(4-cyclopropylmorpholin-3-yl)methyl]acetamide 

Relevant academic research and scientific papers

USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA

This invention is related to the use of inhibitors of vascular endothelial growth factor receptor 3 for treating hepatocellular carcinoma.

PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to derivatives of pyridino-pyridinones, and to their preparation and use thereof, having activity as inhibitors of kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand receptors, said derivatives comprising compounds of formula (I): wherein the various substituent groups are more specifically defined herein. The compounds are suitable as therapeutics for the treatment of various proliferative diseases.

ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF

The invention relates to pyridine-pyridinone derivatives general formula (I): in which R1, R2, R3, R4, n, n′, V, W, Y, Z, Ar are as defined in the description, and to their methods of preparation and their therapeutic applications.

2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS

The invention relates to the compounds of general formula (I): Preparation process and therapeutic use.

2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

The invention relates to the compounds of general formula (I): Preparation process and therapeutic use.

ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The disclosure concerns heterobicyclic compounds of general formula (I) and acid addition salts, hydrates and solvates thereof, as well as enantiomers, diastereoisomers and mixtures thereof. Methods for preparing the compounds, pharmaceutical compositions, and methods of treatment also are disclosed.

PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The present invention relates to pyridopyridone derivatives of formula (I): in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.

DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The disclosure relates to 7-alkynyl-1,8-naphthyridones of formula (I): wherein R1, R2, R3, and R4 are as defined in the disclosure, to compositions containing them, to processes for preparing them, and to their use in therapeutics.

DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The disclosure relates to compounds of formula (I): wherein R1, R2, R3, and R4 are as defined in the disclosure, to compositions containing them, to processes for preparing them, and to their use in therapeutics.